CEO Shaw to leave Ambri
Monday, 24 March, 2003
Dr Joe Shaw, the managing director and CEO of Sydney-based biosensor specialist Ambri (ASX: ABI), has resigned from the company and will return to the US.
He will be replaced at the helm by non-executive director David Cornelius until a new, permanent CEO can be found. Cornelius is on secondment from his position as executive director of Ambri partner Dow Corning's new ventures division.
Shaw, who joined the company almost four years ago, had helped usher in "substantial progress towards commercialisation" of Ambri's biosensor technology, said company chairman Dr John Eady in a statement.
He said Cornelius, with the help of new COO Dr Jonathan Wright, would "provide new and valuable skills and experience needed to lead Ambri through the next phases pf its development."
Shaw said he expected to return to the US at Easter but said he would not comment further at this time. Cornelius was not available for comment by press time.
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...